FAQ

Neurobehavioral Manifestations

Known as: Manifestation, Cognitive, Cognitive Manifestation, Cognitive Symptom 
Signs and symptoms of higher cortical dysfunction caused by organic conditions. These include certain behavioral alterations and impairments of… (More)
National Institutes of Health

Topic mentions per year

Topic mentions per year

1981-2018
010020019812018

Related topics

Related topics

2 relations
aspects of radiation effectsphysiological aspects

Related mentions per year

Related mentions per year

1936-2018
19401960198020002020
Neurobehavioral Manifestations
physiological aspects
aspects of radiation effects

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2011
Highly Cited
2011
Resolving controversies on the path to Alzheimer's therapeutics
Alzheimer's disease constitutes a personal and societal tragedy of immense proportions. Since 1960, research in laboratories and… (More)
  • figure 1
  • figure 2
Is this relevant?
Highly Cited
2010
Highly Cited
2010
Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade.
Currently available evidence strongly supports the position that the initiating event in Alzheimer's disease (AD) is related to… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
Highly Cited
2010
Highly Cited
2010
The American College of Rheumatology preliminary diagnostic criteria for fibromyalgia and measurement of symptom severity.
OBJECTIVE To develop simple, practical criteria for clinical diagnosis of fibromyalgia that are suitable for use in primary and… (More)
  • figure 1
  • table 1
  • table 2
  • figure 2
  • table 3
Is this relevant?
Highly Cited
2004
Highly Cited
2004
NMDA receptor hypofunction produces concomitant firing rate potentiation and burst activity reduction in the prefrontal cortex.
Cognitive deficits associated with frontal lobe dysfunction are a determinant of long-term disability in schizophrenia and are… (More)
  • figure 1
  • figure 2
  • figure 4
  • figure 3
  • figure 5
Is this relevant?
Highly Cited
2003
Highly Cited
2003
Decreased beta-amyloid1-42 and increased tau levels in cerebrospinal fluid of patients with Alzheimer disease.
CONTEXT Alzheimer disease (AD) is characterized by pathological results at autopsy of amyloid plaques and tau-associated… (More)
Is this relevant?
Highly Cited
2003
Highly Cited
2003
The Clinical Global Impression-Schizophrenia scale: a simple instrument to measure the diversity of symptoms present in schizophrenia.
OBJECTIVE To describe the development and validation of the Clinical Global Impression-Schizophrenia (CGI-SCH) scale, designed to… (More)
Is this relevant?
Highly Cited
2001
Highly Cited
2001
Evaluation of CSF-tau and CSF-Abeta42 as diagnostic markers for Alzheimer disease in clinical practice.
OBJECTIVE To evaluate the diagnostic potential of cerebrospinal fluid (CSF) levels of tau and beta-amyloid protein ending at… (More)
Is this relevant?
Highly Cited
2001
Highly Cited
2001
Positron emission tomography in evaluation of dementia: Regional brain metabolism and long-term outcome.
CONTEXT Deficits in cerebral glucose utilization have been identified in patients with cognitive dysfunction attributed to… (More)
  • table 1
  • table 2
Is this relevant?
Highly Cited
1998
Highly Cited
1998
D-serine added to antipsychotics for the treatment of schizophrenia.
BACKGROUND Hypofunction of N-methyl-D-aspartate (NMDA) subtype glutamate receptor has been implicated in the pathophysiology of… (More)
Is this relevant?
Highly Cited
1997
Highly Cited
1997
Ketamine-Induced Exacerbation of Psychotic Symptoms and Cognitive Impairment in Neuroleptic-Free Schizophrenics
The N-methyl-d-aspartate (NMDA) receptor has been implicated in the pathophysiology of schizophrenia. We administered… (More)
  • table 1
  • table 2
  • figure 1
  • figure 1
Is this relevant?